The Apex Set – Retatrutide 30 mg + IGF-1 LR3 1 mg
For In Vitro Research Use Only
Not for Human or Veterinary Application
Set Overview
The Apex Set pairs a next-generation triple-receptor incretin / glucagon agonist with a long-acting IGF-1 analog, enabling parallel research into metabolic and anabolic signaling axes in cell-based and preclinical models. Retatrutide is a synthetic acylated peptide that simultaneously activates the GLP-1, GIP, and glucagon (GCG) receptors — three class B GPCRs governing distinct but overlapping nodes of energy homeostasis. IGF-1 LR3 (Long Arg3 Insulin-like Growth Factor-1) is an 83-amino acid IGF-1 analog with reduced IGF-binding protein affinity and extended in vitro half-life, used to study IGF-1R-mediated PI3K / Akt / mTOR and Ras / MAPK / ERK signaling. Each component ships as its own individually-labeled vial of lyophilized powder, third-party verified at ≥99% purity.
Components
-
Retatrutide — 30 mg · CAS 2381089-83-2 · MW 4,969.6 Da · GLP-1 / GIP / GCG triple receptor agonist · Purity ≥99.4%
-
IGF-1 LR3 — 1 mg · CAS 946870-92-4 · MW ~9,111 Da · 83-AA IGF-1 analog (Arg3 substitution + 13-residue N-terminal extension) · Purity ≥99.4%
-
Form: Lyophilized Powder (each vial)
-
Storage: -20°C long-term; 4°C short-term; avoid repeated freeze-thaw cycles for IGF-1 LR3
Research Context
Retatrutide acts at GLP-1R, GIPR, and GCGR — three class B G protein-coupled receptors involved in insulin secretion, gluconeogenesis suppression, lipolysis, and thermogenesis. The inclusion of GCGR agonism distinguishes retatrutide from dual incretin agonists and enables research into how glucagon receptor signaling modulates outcomes when combined with incretin co-stimulation. It is studied in NAFLD-relevant in vitro models, hepatic glucose production, and adipose tissue fatty acid oxidation. IGF-1 LR3 activates IGF-1R, a receptor tyrosine kinase initiating autophosphorylation and downstream PI3K / Akt / mTOR and Ras / MAPK / ERK cascades involved in cell proliferation, protein synthesis regulation, and apoptosis suppression. The Arg3 substitution and N-terminal extension reduce IGFBP-3 / IGFBP-5 sequestration, making it the preferred IGF-1 analog for long-duration cell culture experiments. The combination supports research probing the interplay between systemic metabolic regulation (via incretin / glucagon receptor signaling) and tissue-level anabolic signaling (via IGF-1R) in shared experimental contexts including myoblast differentiation, satellite cell activation, hepatocyte glucose handling, and IGF-1R / insulin receptor cross-reactivity studies.
Note on Retatrutide dosing. The Retatrutide vial in this set is the 30 mg presentation. The 10 mg vial featured in the bundle photography is temporarily out of stock and we are working to restock it. Once 10 mg is back in stock, this set will switch back to the 10 mg vial. The current bundle price has been adjusted to reflect the 30 mg substitution.
Intended Use
This set is intended strictly for in vitro laboratory research by qualified professionals.
It is not approved for:
Regulatory Disclaimer
-
These compounds have not been evaluated by the U.S. Food and Drug Administration (FDA).
-
They are not intended to diagnose, treat, cure, or prevent any disease.
-
All handling and use must comply with applicable institutional, local, state, and federal regulations.
Terms of Sale
By purchasing from Axis Peptide Labs, the buyer confirms that they are a qualified researcher, laboratory, or institution and acknowledges that the products are for research use only.
-
All sales are final.
-
The purchaser assumes full responsibility for compliant handling, storage, and use.
-
Resale for human consumption is strictly prohibited.
